Filing Flows › Scribe Therapeutics (SCTX) › Q2 2026 › vs Q2 2025
Scribe Therapeutics (SCTX) Q2 2026 vs Q2 2025 (year over year)
Scribe Therapeutics's revenue fell $3.0M (-61%) from $4.9M in Q2 2025 to $1.9M in Q2 2026.
Scribe Therapeutics, Q2 2026: revenue $1.9M (-61% year over year), operating margin -489.8%, net loss $6.5M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.9M | $4.9M | −$3.0M | -61% |
| Other income, net | $3.1M | $1.0M | $2.1M | +209% |
| Net loss | $6.5M | $9.9M | −$3.4M | -35% |
| Costs & expenses | $11.5M | $16.5M | −$5.0M | -30% |
| Operating costs | $11.3M | $16.5M | −$5.2M | -32% |
| Income tax | $212K | −$712K | $924K | — |
| Research & development | $8.8M | $13.9M | −$5.1M | -36% |
| General & admin | $2.5M | $2.6M | −$151K | -6% |
Questions
How much did Scribe Therapeutics's revenue grow year over year in Q2 2026?
Scribe Therapeutics's revenue fell $3.0M (-61%) from $4.9M in Q2 2025 to $1.9M in Q2 2026.